Abstract Background and objectives: It has become evident that fibromodulin and other members of the proteoglycan family are not only involved in collagen fibrillogenesis and cell adhesion but they also contribute to modulation of cytokine activity, suppression of tumor growth, and prevention of apoptosis. Fibromodulin has been characterized as one of the tumor associated antigens (TAA) in B cell chronic lymphocytic leukemia (B-CLL) with the potential to elicit specific antitumor response and it is considered as good candidate for immunotherapy. Aim of work: to study the expression of fibromodulin at the gene level of B-cell chronic lymphocytic leukemia patients, in comparison to normal controls and to asses its role in the pathophysiology of CLL. Patients and methods: Fibromodulin gene expression was tested by one step reverse transcriptionpolymerase chain reaction (RT-PCR) in peripheral blood mononuclear cells of 30 patients with B-CLL as well as in 20 age and sex matched healthy volunteers. Results: In this study, fibromodulin gene was expressed in 46.7% of patients with B-CLL which was significantly different from the control age and sex matched healthy volunteers in which none of them showed peripheral blood mononuclear cells positivity for fibromodulin gene expression (0%) (p-value =0.006). We also found significant associations between higher fibomodulin gene expression and some risk factors in the studied CLL cases such as hepatomegaly, lower haemoglobin level, lower * Corresponding author. Tel.: +20 0105004325. E-mail address: rania_sami1976@yahoo.com (R. Mohamed Samy).
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for B-CLL, but due to the high treatment-related mortality and advanced age of most patients, the procedure is not applicable for the majority of B-CLL patients. B-CLL is a very attractive disease to be targeted by immunotherapy due to its rather low progression and due to the availability of cancer cells in the peripheral blood [1] . Immunotherapy promises to mitigate the complications of chemotherapy and potentially provide for curative treatment [2] . Vaccine approaches in this disease have largely focused on inducing effective autologous immune mediated responses against tumor antigens expressed on the CLL cells. It has also been demonstrated that CLL cells are very effective targets of the allogenic graft versus leukemia effect and there is considerable interest in developing strategies to exploit this phenomenon, particulary following reduced intensity conditioning allogeneic stem cell transplantation. If successful, using the immune system to treat this otherwise incurable disease could provide an approach that is distinct from traditional chemotherapy [3] . Recently, it has been described that vaccination with allogenic dendritic cells (DCs) pulsed with tumor cell lysate generated specific cytotoxic CD8 + T cell response against the leukemia-associated antigens, such as fibromodulin, which have been detected in patients with B-CLL [4] . For the development of T-cell based therapies, the definition of immunogenic tumorassociated antigens (TAAs), which are expressed in malignant cells from leukemia/cancer patients but not in tissues of healthy volunteers, constitutes a cornerstone. RHAMM/CD168, fibromodulin, survivin and the oncofetal antigen immature lamininreceptor protein (OFAiLRP) have been characterized as TAAs in B-CLL with the potential to elicit specific anti-tumor response and considered as good candidate targets for immune therapy [5] . Fibromodulin mRNA has been detected in a variety of clinical malignancies, such as lung, breast, and prostate carcinomas. Fibromodulin has a role in regulating stroma ECM structure and fluid balance in carcinoma [6] . Through study of the global gene expression profile of B-cell chronic lymphocytic leukemia (B-CLL) cells, fibromodulin was found to be one of the most overexpressed genes [7] .
Our work aimed at studying the expression of fibromodulin gene in CLL patients as a target for immunotherapy.
Patients, materials, and methods
The present study was conducted on 30 newly diagnosed chronic lymphocytic leukemia patients during the period from March 2009 to February 2010 among cases referred to the Medical Oncology Department of Kasr El-Aini hospitals, Cairo University after taking informed consents. Criteria for diagnosis of CLL according to the National Cancer Institute-Working group (NCI-WG) were applied. The diagnosis was based on coexpression of (CD5 + /CD19 + /CD23 + /light chain restriction/weak expression of sIg) by immunophenotyping and on the presence of more than 5.0 · 10 9 /L lymphocytes in peripheral blood. They were 23 male (76.7%) and 7 females (23.3%) with male to female ratio of 3.3:1. Their age ranged between 39 and 79 years with a median 60.5 years. Twenty apparently healthy age and sex matched adults were enrolled as a control group after taking informed consents. They were 14 male (70%) and 6 females (30%) with male to female ratio of 2.3:1. Their age ranged between 40 and 65 years with a median 55.5 years.
Five milliliters of venous blood were taken from each patient and control under complete aseptic precautions on 1.5 mg/ml ethylene diamine tetra-acetic acid (EDTA) and were divided for complete blood picture and the study of fibromodulin gene expression by RT-PCR.
Total RNA was extracted from tumor cells and normal PBMCs using QIAamp RNA extraction kit (QIAGEN, Catalog number: 52304) according to the manufacturer's instructions (according to QIAamp RNA blood Mini Handbook, 2006). Fibromodulin detection by one step RT-PCR was performed using the QIAGEN OneStep RT-PCR Kit. (QIAGEN, Catalog number: 210210, Germany). First-strand cDNA was synthesized using 8 lg total RNA in 50 lL reaction mixture consisting of 24 lL RNase-free water, 10 lL QIAGEN One-
Step RT-PCR Buffer (5· concentrated, containing TrisAECl, KCl, (NH 4 ) 2 SO 4 , 12.5 mM MgCl 2 , dithiothreitol DTT; 12.5 mM MgCl 2 , pH 8.7), 2 lL dNTP Mix (containing 10 mM of each dNTP), 2 lL QIAGEN OneStep RT-PCR Enzyme Mix (Omniscript and Sensiscript Reverse Transcriptases and HotStarTaq DNA Polymerase) and 2 lL of each forward and reverse primers (5 lM each). The mixture was incubated in thermal cycler (PERKIN ELMER PCR system 9600, USA) at 42°C for 45 min for reverse transcription and initial activation step was performed for 15 min at 95°C. PCR amplification was performed using fibromodulin-specific primers 5 0 -ACCGTCCCCGATAGCTACTT-3 0 as sense and 5 0 -CAT-CCTGGACCTTCCAGCAAA-3 0 as antisense [7] . PCR was performed for 35 cycles at 92°C for 30 s (denaturation), 60°C for 30 s (annealing), and 72°C for 30 s (extension). The amplified products were separated on 2% agarose gel electrophoresis, stained with ethidium bromide and visualized under UV light. The results were documented using a Polaroid camera with a red orange filter. The sample was considered positive when a clear, sharp, distinct band was observed at the specific molecular weight 480 bp. b-Globin gene was used as a control for the quality of cDNA with sense primer 5 0 -CAACTTCATCCACGTTCACC-3 0 and reverse primer 5 0 -GAAGAGCCAAGGACAGGTTAC-3 0 . PCR was performed for 35 cycles at 94°C for 60 s, 58°C for 60 s and 72°C for 60 s. The amplified products were separated on 2% agarose gel electrophoresis and positive sample showed a clear, sharp band at 268 bp. The size of the amplified product was read with the use of a DNA ladder of different molecular weights (fermentas, NoLimitsä 100 bp DNA Fragment, Catalog number: SM1441).
Statistical methods:
Data were statistically described in terms of range, mean, standard deviation (SD), median, frequencies (number of cases) and percentages when appropriate. Comparison of quantitative variables between the study groups was done using the Mann-Whitney test for independent samples. For comparing categorical data, the Chi square (x) test was performed. Exact test was used instead when more than 20% of cells have the expected frequency is less than 5. A probability value (p-value) less than 0.05 was considered statistically significant. All statistical calculations were done using computer programs Microsoft Exel 2003 (Microsoft Corporation, NY, USA) and SPSS (Statistical package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.
Results
The present study was conducted on 30 chronic lymphocytic leukemia patients. They were 23 male (76.7%) and 7 females (23.3%) with male to female ratio of 3.3:1. Their age ranged between 39 and 79 years with a median of 60.5 years. There were twenty apparently healthy age and sex matched adults as a control group. They were 14 males (70%) and 6 females (30%) with male to female ratio of 2.3:1. Their age ranged from 40 to 65 years with a median 55.5 years. Results of fibromodulin gene expression: CLL patients and controls were subjected to one step RT-PCR, 14/30 were positive (46.7%) for fibromodulin gene expression, while all of the control group were negative 20/20 (100%) (p-value = 0.006). (Fig. 1 and Table 1 ).
The main clinical characteristics of the CLL patients included in our study (risk factors according to the modified Rai staging system) are summarized in Table 2 .
Relationships between fibromodulin gene expression and different risk factors were studied. Patients with lymphadenopathy or splenomegaly had higher percentage of positive fibromodulin gene expression (60%) compared with those without The duration since diagnosis ranged between 0 and 12 months with a mean value 5.26 ± 4.03. * Anemia (Hb < 11 g/dL), thrombocytopenia (Plts < 100 · 10 9 /L) according to the Rai staging system [12] . (Table 3) . As regarding laboratory data, significant relations were detected between fibromodulin gene expression and lower hemoglobin level (<11 g/dl) (p-value = 0.020), lower RBCs count (p-value = 0.042) and lower platelet count (<100 · 10 9 /L) (p-value = 0.011) but insignificant relations were detected with TLC count (p-value = 0.480) and lymphocytic count (p-value = 0.707), (Table 4) .
Discussion
There are several considerations that make antileukemic vaccination a potential therapeutic approach for CLL. Firstly, the majority of CLL patients has advanced age and need treatment options with low toxicity. Secondly, most of the patients have a long period of indolent disease which does not need aggressive intervention. Thirdly, the utility of an antileukemic immune response in controlling the disease is emphasized by the graft-versus-leukemia effect associated with allogeneic stem cell transplants and donor lymphocyte infusions [8] .
CLL should be an ideal target for immune-mediated responses. CLL arises from B cells that can act as antigen-presenting cells (APCs), express unique tumor antigens, and has been shown to be a target for the allogeneic T cells which mediate a graft-versus-leukemia effect [9] . B-CLL cells may express or overexpress a number of tumor-associated antigens (TAAs) that can be the target of specific cytotoxic T-lymphocyte (CTL) responses like fibromodulin [4] .
Our study aimed at studying fibromodulin gene expression in CLL patients as a good target for immunotherapy. Analysis of results of one step RT-PCR for detection of fibromodulin gene among the studied groups revealed the following results: fibromodulin gene was expressed in 14 of 30 CLL patients (46.7%), it was not expressed in all the control groups 0/20 (0%).
Our results are comparable to the study of Giannopoulos et al., in 2006 who found several expression patterns of TAAs in B-CLL patients versus healthy volunteers (HVs). B-CLL patients and healthy Volunteers (HVs) were examined by conventional and quantitative RT-PCR for mRNA of fibromodulin and other tumor associated antigens, more than half of the examined B-CLL patients showed positive mRNA expression for fibromodulin (63%) but not in HV [4] . While, in another study, Mikaelsson et al. [5] reported that fibromodulin expression was noticed at the gene level, using both RT-PCR and Real-time quantitative PCR, in all patients with B-CLL (100%) and in most patients with mantle cell lymphoma (MCL). No mutations in the fibromodulin gene were detected. Fibromodulin was also detected at the protein level in the cytoplasm of the B-CLL cells and in the supernatant after in vitro cultivation, but not at the cell surface. They also found that fibromodulin was not expressed in patients with T-cell chronic lymphocytic leukemia (T-CLL), B-cell prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), hairy cell leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or chronic myelogenous leukemia (CML) or in 36 hematologic cell lines. Normal blood mononuclear cells (T and B lymphocytes, monocytes), tonsil B cells, and granulocytes did not express fibromodulin [5] . They concluded that understanding the biologic functions of fibromodulin in B-CLL/MCL is critical because this unique molecule may be used as a target for therapeutic intervention [2] . This is also in agreement with Mayr et al. [10] , who reported that fibromodulin is highly overexpressed in CLL cells (100%) compared with normal B lymphocytes by gene expression profiling. In their study, over expression of fibromodulin using real time RT-PCR was observed for all leukemic samples at the mRNA level, while expression of fibromodulin was not detected in chronic myeloid leukemia (CML) patients, acute lymphoblastic leukemia (ALL) patients and in peripheral blood mononuclear cells (PBMCs) of healthy donors tested. The lower frequency of fibromodulin gene expression in our studied cases (46.7%) in comparison to the other mentioned studies which were 63% by Giannopoulos et al. [4] , 100% by Mikaelsson et al. [5] and 100% by Mayr et al. [10] might be attributed to more sensitive techniques used by them.
The modified Rai staging system classifies CLL patients into low-risk patients with only lymphocytosis in the PB and BM (stage 0), intermediate-risk patients with lymphocytosis and lymphadenopathy (stage I) and/or hepato-splenomegaly (stage II) and high-risk patients with lymphocytosis together with anemia (Hb < 11 g/dL) (stage III) and/or thrombocytopenia (Plts < 100 · 10 9 /L) (stage IV). In an attempt to correlate fibromodulin gene expression with risk factors in CLL according to the Rai staging system which is the most commonly used in CLL; our data revealed that fibromodulin gene expression was significantly higher among patients with hepatomegaly (p-value = 0.030) and borderline significantly higher among patients with lymphadenopathy (p-value = 0.058) and splenomegaly (p-value = 0.058). Significant relations were also detected between fibromodulin gene expression and lower hemoglobin level (p-value = 0.020), lower RBCs count (p-value = 0.042) and lower platelet count (p-value = 0.011). There were insignificant relations regarding TLC count (p-value = 0.480) and lymphocytic count (p-value = 0.707). These results indicate that expression of fibromodulin gene may have a role in the pathogenesis of CLL being related to higher risk factors, but more prospective studies on higher number of cases may be needed to support its possible role in the pathophysiology of CLL. Follow up of patients is highly recommended to discuss the prognostic role of the fibromodulin gene.
